Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy


      Twenty-six patients with prostate cancer status post-radical prostatectomy who were candidates for salvage radiation therapy (SRT) underwent lymphotropic nanoparticle enhanced MRI (LNMRI) using superparamagnetic nanoparticle ferumoxtran-10. LNMRI was well tolerated, with only two adverse events, both Grade 2. Six (23%) of the 26 patients, previously believed to be node negative, tested lymph node positive by LNMRI. A total of nine positive lymph nodes were identified in these six patients, none of which were enlarged based on size criteria.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Catalona WJ
        • Smith DS
        5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.
        J Urol. 1994; 152: 1837-1842
        • Kupelian PA
        • Katcher J
        • Levin HS
        • Klein EA
        Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 1997; 37: 1043-1052
        • Moul JW
        Prostate specific antigen only progression of prostate cancer.
        J Urol. 2000; 163: 1632-1642
        • Cox JD
        • Gallagher MJ
        • Hammond EH
        • Kaplan RS
        • Schellhammer PF
        Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.
        J Clin Oncol. 1999; 17: 1155
        • Pollack A
        • Hanlon AL
        • Pisansky TM
        • Sandler HM
        A multi-institutional analysis of adjuvant and salvage radiotherapy after radical prostatectomy.
        ASTRO. 2004; 60: S186
        • Chawla AK
        • Thakral HK
        • Zietman AL
        • Shipley WU
        Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors.
        Urology. 2002; 59: 726-731
        • Parker C
        • Warde P
        • Catton C
        Salvage radiotherapy for PSA failure after radical prostatectomy.
        Radiother Oncol. 2001; 61: 107-116
        • Weissleder R
        • Elizondo G
        • Wittenberg J
        • Rabito CA
        • Bengele HH
        • Josephson L
        Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging.
        Radiology. 1990; 175: 489-493
        • Harisinghani MG
        • Saini S
        • Weissleder R
        • et al.
        MR Lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation.
        AJR Am J Roentgenol. 1999; 172: 1347-1351
        • Wunderbaldinger P
        • Josephson L
        • Bremer C
        • Moore A
        • Weissleder R
        Detection of lymph node metastases by contrast-enhanced MRI in an experimental model.
        Magn Reson Med. 2002; 47: 292-297
        • Harisinghani MG
        • Barentsz J
        • Hahn PF
        • et al.
        Noninvasive detection of clinically occult lymph-node metastases in prostate cancer.
        N Engl J Med. 2003; 348: 2491-2499
        • Pisansky TM
        • Kozelsky TF
        • Myers RP
        • et al.
        Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.
        J Urol. 2000; 163: 845-850
        • Cher ML
        • Bianco Jr., FJ
        • Lam JS
        • et al.
        Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy.
        J Urol. 1998; 160: 1387-1391
        • Sodee DB
        • Malguria N
        • Faulhaber P
        • Resnick MI
        • Albert J
        • Bakale G
        Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers.
        Urology. 2000; 56: 988-993
        • Fricke E
        • Machtens S
        • Hofmann M
        • et al.
        Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
        Eur J Nucl Med Mol Imaging. 2003; 30: 607-611
        • Stephenson AJ
        • Shariat SF
        • Zelefsky MJ
        • et al.
        Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
        JAMA. 2004; 291: 1325-1332
        • Scattoni V
        • Picchio M
        • Suardi N
        • et al.
        Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.
        Eur Urol. 2007; 52: 423-429